AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19326811
Drug: Piper longum
RxNorm normalized name: piper longum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piper longum (30 mg)
Trial: 15298338
Drug: Insulin detemir/insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin detemir/insulin aspart
Trial: 11515348
Drug: Lansoprazole suspension
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole suspension (30 mg via nasogastric tube)
Trial: 11515348
Drug: Lansoprazole intact
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole intact capsule
Trial: 11515348
Drug: Lansoprazole suspension
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole suspension and intact capsule
Trial: 10351117
Drug: LW 50020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LW 50020 (Luivac; Paspat oral), taken once daily for two periods of 4 weeks each, with a treatment-free interval of 4 weeks.
Trial: 18367956
Drug: Bolus recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus recombinant factor VIII (rFVIII) 25 to 50 IU/kg given 6, 14, 24, 36, 48, and 60 hours after loading dose
Trial: 17138770
Drug: Mifepristone, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone, 5 mg daily for 26 weeks
Trial: 638119
Drug: Daily supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplements of 20-30 mg inorganic iron as ferrous sulphate for 3.5, 7, and 12 months
Trial: 17469936
Drug: Modafinil (1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (1.75 mg/kg, 3.50 mg/kg, or 7.00 mg/kg)
Trial: 17469936
Drug: d-Amphetamine (0.035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-Amphetamine (0.035 mg/kg, 0.070 mg/kg, 0.140 mg/kg)
Trial: 9809846
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (100 mg x kg(‐1) administered at 0, 30, 60, and 90‐min post‐race)
Trial: 18221638
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids supplemented diet (EPA + DHA, enriched in salmon 150 g/day, 3 times/week)
Trial: 9783928
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with mitomycin C (40 mg) followed by BCG (6 weekly instillations)
Trial: 9783928
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C only (10 weekly instillations)
Trial: 7848896
Drug: Immediate-release isosorbide
RxNorm normalized name: isosorbide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release isosorbide dinitrate (ISDN) 15-120 mg in a qid regimen
Trial: 7848896
Drug: Asymmetric tid
RxNorm normalized name: An asymmetric immunoglobulin G1 (IgG1)-based, B-cell maturation antigen (BCMA) x CD3 T-cell bispecific monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asymmetric tid therapy with 30 mg of ISDN (7 a.m., 1 p.m., and 6 p.m.)
Trial: 7848896
Drug: Asymmetric bid
RxNorm normalized name: An asymmetric immunoglobulin G1 (IgG1)-based, B-cell maturation antigen (BCMA) x CD3 T-cell bispecific monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asymmetric bid therapy with ISDN at 7 a.m. and noon
Trial: 7848896
Drug: Immediate-release isosorbide-5-mononitrate
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate-release isosorbide-5-mononitrate (IS-5-MN) 10 and 20 mg given bid
Trial: 7848896
Drug: Once-daily controlled-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily controlled-release IS-5-MN
Trial: 3140580
Drug: 17 alpha-hydroxyprogesterone
RxNorm normalized name: 17 alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha-hydroxyprogesterone caproate (17HPC, Proluton Depot) 500 mg intramuscularly weekly for 6-16 weeks
Trial: 3140580
Drug: 17 alpha-hydroxyprogesterone
RxNorm normalized name: 17 alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha-hydroxyprogesterone caproate (17HPC) 500 mg intramuscularly weekly
Trial: 3140580
Drug: 17 alpha-hydroxyprogesterone
RxNorm normalized name: 17 alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha-hydroxyprogesterone caproate (17HPC) 250 mg intramuscularly weekly
Trial: 3140580
Drug: Contraceptive pill
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive pill (Microgynon)
Trial: 30036596
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with ACE inhibitor-associated angioedema
Trial: 30036596
Drug: ACE inhibitor-treated
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor-treated controls
Trial: 26871954
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (1 ml of 40 mg/ml methylprednisolone dissolved in 4 ml lidocaine)
Trial: 26871954
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (1 ml isotonic saline mixed with 4 ml lidocaine)
Trial: 22708259
Drug: Rapid titration
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid titration
Trial: 15076242
Drug: Nucleoside analogue
RxNorm normalized name: Nucleoside analogue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside analogue treatment; venous lactate measured according to AACTG guidelines.
Trial: 9669015
Drug: Chloromycetin ointment
RxNorm normalized name: chloroacetate
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloromycetin ointment (group O)
Trial: 3278390
Drug: Radiation concurrent
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation concurrent with cisplatinum
Trial: 3278390
Drug: Twice a
RxNorm normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice a day irradiation with 120 cGys up to 6,000 cGys
Trial: 15103479
Drug: Systemic antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotic treatment
Trial: 23184140
Drug: Biological material
RxNorm normalized name: Microbiological material
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological material TOT (PELVILACE® TO)
Trial: 18394162
Drug: Drotrecogin alfa
RxNorm normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotrecogin alfa (activated; DrotAA) at a dosage of 24 mug/kg per hour for 96 hours
Trial: 1785247
Drug: Oral atropine
RxNorm normalized name: atropine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral atropine 0.03 mg/kg (Group A)
Trial: 1785247
Drug: i.v. glycopyrrolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. glycopyrrolate 0.005 mg/kg (Group G)
Trial: 24758078
Drug: Ginkgo Leaves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo Leaves Tablet (GLT), 19.2 mg each time, three times daily for 12 months
Trial: 6189039
Drug: Responders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders to chemotherapy
Trial: 387151
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose flupenthixol decanoate
Trial: 387151
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose flupenthixol decanoate
Trial: 30273016
Drug: Oral nutrition
RxNorm normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutrition supplementation (ONS) for 7 days before surgery
Trial: 26811519
Drug: Etoposide 50
RxNorm normalized name: etoposide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide 50 mg/m2 and cisplatin 50 mg/m2 plus concurrent thoracic radiation therapy (60 to 66 Gy) followed by two cycles of consolidation platinum-based doublet chemotherapy (arm B)
Trial: 9038463
Drug: Glycopyrrolate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 0.3 mg
Trial: 22243938
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline solution (HSS)
Trial: 18544724
Drug: Melatonin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (2.5 mg)
Trial: 18544724
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (bright light + melatonin)
Trial: 15780736
Drug: High-dose combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose combined hepatitis A and B vaccine administered in two doses (0, 6 months)
Trial: 15780736
Drug: Paediatric-dose combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paediatric-dose combined hepatitis A and B vaccine administered in three doses (0, 1, 6 months)
Trial: 14504024
Drug: Three-session motivational
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-session motivational enhancement therapy (MET alone)
Trial: 1627421
Drug: Breast-conserving therapy
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-conserving therapy (lumpectomy, axillary clearance, and radiotherapy to the breast: 50 Gy external irradiation in 5 weeks followed by boost with iridium implant of 25 Gy)
Trial: 6744790
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion at 0.01 micrograms min‐1 kg‐1
Trial: 6744790
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion at 0.1 micrograms min‐1 kg‐1
Trial: 29242000
Drug: Social recovery
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social recovery therapy plus early intervention services
Trial: 11976161
Drug: xoi gac
RxNorm normalized name: Xoimenia americana seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xoi gac (3.5 mg beta-carotene per serving)
Trial: 11976161
Drug: rice mixed
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rice mixed with synthetic beta-carotene powder (5.0 mg)
Trial: 8890080
Drug: Commercial available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial available preterm infant formula (2% protein, 40 mg glycine/dl)
Trial: 6391269
Drug: Fentanyl infusion
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl infusion (2 micrograms/kg/hour)
Trial: 24074777
Drug: Response-guided approach
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response-guided approach for hormone-positive tumors
Trial: 24074777
Drug: Increasing number
RxNorm normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increasing number of chemotherapy cycles
Trial: 24074777
Drug: Adding bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adding bevacizumab in TNBC treatment
Trial: 8258986
Drug: Mechanical pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical pressure therapy (MPT)
Trial: 24655114
Drug: no infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no infusion
Trial: 24655114
Drug: oesophageal acid
RxNorm normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oesophageal acid infusion
Trial: 19939872
Drug: Org 26828
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 26828 at higher doses
Trial: 18369631
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of radiographic features
Trial: 12522402
Drug: Prophylactic injection
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic injection of bupivacaine with adrenaline
Trial: 10643842
Drug: Palivizumab (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palivizumab (monoclonal antibody to the F protein of RSV)
Trial: 21211651
Drug: Low-dose fluticasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fluticasone
Trial: 17845685
Drug: H(2) antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H(2) antagonist + furazolidone + one other antibiotic
Trial: 17845685
Drug: Bismuth-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based triple therapies
Trial: 11524192
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia plus intracameral lidocaine 1%
Trial: 8568016
Drug: Nicoderm (nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicoderm (nicotine transdermal system), 21 mg/day applied for 24 hours
Trial: 8568016
Drug: Controlled smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled smoking (30 cigarettes at half‐hourly intervals on days 1 and 5; ad libitum smoking on days 2‐4)
Trial: 28633671
Drug: Prucalopride 2
RxNorm normalized name: prucalopride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride 2 mg/day
Trial: 26251066
Drug: Amoxicillin combined
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin combined with sulbactam
Trial: 24001747
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (50-μg/d)
Trial: 12954158
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg daily for 12 months)
Trial: 2160516
Drug: 10^4 PFU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10^4 PFU dose of rhesus rotavirus vaccine
Trial: 2160516
Drug: 10^3 PFU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10^3 PFU dose of rhesus rotavirus vaccine
Trial: 31917835
Drug: Somapacitan 0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somapacitan 0.16 mg/kg/wk
Trial: 24552372
Drug: Leucine supplementation
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine supplementation (7 g leucine, 93 kcal, 14.5 g whey-based protein)
Trial: 24552372
Drug: Isocaloric isonitrogenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric isonitrogenous control (0.3 g LEU, 93 kcal, 11.3 g collagen protein)
Trial: 27993418
Drug: Intravenous Ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Ketorolac 30 mg
Trial: 27993418
Drug: Rescue analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue analgesic (Intravenous morphine 0.1 mg/kg)
Trial: 19956961
Drug: Laparoscopic ovarian
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic ovarian drilling (LOD) and CC
Trial: 7738616
Drug: No BK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No BK virus excretion
Trial: 17584555
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg, 3 times a day)
Trial: 11530028
Drug: Fluvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (20 mg initial dose, titrated to 80 mg if needed)
Trial: 9506347
Drug: Accelerated hyperfractionated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hyperfractionated thoracic radiotherapy (AHTRT) with or without chemotherapy
Trial: 9506347
Drug: Accelerated hyperfractionated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hyperfractionated thoracic radiotherapy (AHTRT) with chemotherapy
Trial: 7997863
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g paracetamol (as propacetamol) intravenously
Trial: 3287974
Drug: Cefoxitin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (3 perioperative doses of 2 g)
Trial: 3287974
Drug: Cefotetan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (2 g single preoperative dose)
Trial: 23233651
Drug: HER2 positive
RxNorm normalized name: RHUMAB HER2
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HER2 positive pre-treatment biopsies
Trial: 17200303
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment with a sling
Trial: 10572606
Drug: MACOP-B (6-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MACOP-B (6-drug weekly chemotherapy regimen for 12 weeks)
Trial: 1852297
Drug: Methoxybutropate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methoxybutropate (300 mg three times a day for eight weeks)
Trial: 30403976
Drug: Early Oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early Oral Feeding (EOF) group
Trial: 30403976
Drug: Late Oral
RxNorm normalized name: Adalate Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late Oral Feeding (LOF) group
Trial: 27822013
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of clopidogrel/aspirin 75/100 mg
Trial: 27822013
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of individual formulations (clopidogrel 75 mg and aspirin 100 mg)
Trial: 21420744
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of psychotropic drugs
Trial: 21420744
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not ceasing drug use)
Trial: 21041350
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care intervention including patient education and choice of medication, therapy, or both.
Trial: 10743445
Drug: placebo suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo suppository
Trial: 1553891
Drug: Bepridil 200
RxNorm normalized name: bepridil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil 200 mg
Trial: 1553891
Drug: Bepridil 300
RxNorm normalized name: bepridil 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil 300 mg
Trial: 1553891
Drug: Bepridil 400
RxNorm normalized name: bepridil 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil 400 mg
Trial: 2581680
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg intrathecal morphine (Group B)
Trial: 2581680
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intrathecal morphine (Group C)
Trial: 2581680
Drug: Prilocaine 100
RxNorm normalized name: prilocaine 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine 100 mg (Group A, Control)
Trial: 20878324
Drug: Intensive Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Insulin Therapy (IIT)
Trial: 20878324
Drug: Conventional Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional Insulin Therapy (CIT)
Trial: 10356917
Drug: Cortexin delivered
RxNorm normalized name: adrenal cortex extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortexin delivered via nasal electrophoresis (NE) in combination with standard therapy
Trial: 8522381
Drug: Ciprofloxacin 200
RxNorm normalized name: ciprofloxacin 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 200 mg twice daily
Trial: 23608797
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition fluid (30 ml·kg(‐1)·d(‐1))
Trial: 23608797
Drug: Traditional intestinal
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional intestinal preparation (fasting, oral antibiotic, cleaning enema)
Trial: 23608797
Drug: Traditional bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional bowel preparation
Trial: 21389858
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of oral flucloxacillin
Trial: 19637415
Drug: Atazanavir and
RxNorm normalized name: atazanavir and ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir and ritonavir combination